A Remarkable Remission: Treating HMA Refractory Transforming MDS with Single-Agent Low-Dose Cytarabine Leading to an Ongoing Six-Year OS

Hypomethylating agents (HMA) are the standard of care for patients ≥65 years with intermediate-high risk myelodysplastic syndrome (MDS) unsuitable for intensive therapy or stem cell transplant (SCT). However, many patients will develop relapse/refractory disease, at which point limited treatment opt...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, David, Jones, Lydia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042518/
https://www.ncbi.nlm.nih.gov/pubmed/32110242
http://dx.doi.org/10.1155/2020/1540370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042518/
https://www.ncbi.nlm.nih.gov/pubmed/32110242
http://dx.doi.org/10.1155/2020/1540370

Ejemplares similares